CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.

   
Presentation Details:
Title: “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks”
Date:  Thursday, December 3, 2020
Time: 10:30 AM (ET)
Location: Digital
Register: https://xconomy.com/xcelerating-life-sciences-new-york/register-now-2/
   

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Katie Gallagher
kgallagher@lavoiehealthscience.com
+1 617-792-3937

Staff

Recent Posts

TKSoftware Inc. Unveils ICONIC Pro: The All-In-One Medical Billing & Clearinghouse Solution

TKSoftware Inc. today launches ICONIC Pro, a unified, cloud–based platform that combines claims submission, electronic…

5 minutes ago

Monarch Athletic Club: A Longevity Clinic Disguised as an Athletic Club

LOS ANGELES, June 23, 2025 /PRNewswire/ -- Monarch Athletic Club, the Los Angeles-based wellness disruptor…

5 minutes ago

ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer

Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years…

3 hours ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for…

6 hours ago

As Dangerous US Heat Wave Intensifies, AccuWeather Urges Public to Rely on Science-Backed RealFeel® Temperature for Accurate Danger Index

AccuWeather's RealFeel® Temperature is the only authentic formula-based metric—unlike 'Feels Like,' which lacks scientific credibility.Request…

6 hours ago

New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty

Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON,…

6 hours ago